Q-omics provides the consensus-scored FAM189B profile across patient tissues and cancer cell-line models. FAM189B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM189B is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, FAM189B RNA expression shows 19,127 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where FAM189B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM189B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM189B survival associations across molecular data types. FAM189B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM189B RNA expression–survival associations across cancer types. High FAM189B expression shows unfavorable associations in ACC, KIRC, LIHC, MESO, LUAD and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM189B RNA expression.
This table summarizes FAM189B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM189B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM189B shows higher tumor expression in HNSC, KIRC, COAD, KIRP, LIHC and LUAD. The HNSC box plot shows higher FAM189B RNA expression in tumor versus normal tissue (log2 FC = +1.158, t-test p < 0.001).
This table shows molecular features associated with FAM189B in patient tissues and cancer cell lines. In patient samples, FAM189B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM189B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
